Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

This Systematic Review assesses the economic impact of Respiratory Syncytial Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource utilization and associated costs. We searched online databases from January 2012 to November 2022 to identify eligible publications. We...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carolina Moreno, Ariel Bardach, María Carolina Palermo, María Macarena Sandoval, Elsa Baumeister, Silvina Ruvinsky, Rolando Ulloa-Gutiérrez, Katharina Stegelmann, Sofía Ardiles Ruesjas, Jorge LaRotta, Rodrigo Sini de Almeida, Agustín Ciapponi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Cost of illness direct cost indirect cost lower respiratory tract infections respiratory syncytial virus
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2381298
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Out-of-pocket costs, time burden, and caregiver quality of life associated with pediatric medically attended respiratory syncytial virus illnesses
by: Angela M. Rose, et al.
Published: (2025-08-01)

THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
by: A. V. Rudakova, et al.
Published: (2012-07-01)

Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States
by: Ahuva Averin, et al.
Published: (2025-12-01)

Cost of illness of RSV infection in a middle-income tropical country
by: Jefferson Antonio Buendía, et al.
Published: (2021-08-01)

The Role of Respiratory Syncytial Virus Infection in the Hospitalization and Mortality of Adults with Congestive Heart Failure in Spain, 2018–2022
by: Rosa María Gómez-García, et al.
Published: (2025-04-01)

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
by: Andrea Marcellusi, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of nirsevimab for prevention of respiratory syncytial virus disease among infants in Shanghai, China: A modeling study
by: Qiang Wang, et al.
Published: (2025-12-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study
by: Denis Sauré, et al.
Published: (2025-04-01)

Healthcare resource utilisation and costs in infants with confirmed respiratory syncytial virus infections: a national population cohort study
by: Hyun Jin Han, et al.
Published: (2024-10-01)

Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants
by: Thomas Shin, et al.
Published: (2025-12-01)

Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus
by: Mostafa Zayed, et al.
Published: (2025-12-01)

Nirsevimab prophylaxis on pediatric intensive care hospitalization for severe acute bronchiolitis: a clinical and economic analysis
by: Sarah Touati, et al.
Published: (2025-04-01)

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands
by: Annefleur C. Langedijk, et al.
Published: (2025-12-01)

Cost effectiveness of a protocol using palivizumab in preterm infants
by: Yolanda Hernández-Gago, et al.
Published: (2017-03-01)

Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico
by: José Luis Huerta, et al.
Published: (2025-01-01)

The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma
by: Hannah Ora Hasson, et al.
Published: (2024-11-01)

Socio-economic burden of respiratory syncytial viral infection of the lower respiratory tract in children aged from birth to 5 years in the Russian Federation: modeling results
by: V. I. Ignatyeva, et al.
Published: (2024-02-01)

The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy
by: Vieri Lastrucci, et al.
Published: (2025-07-01)

Structural Classification Methodology and Assignment of General Shop Costs for the Industrial Company’s Production Cost
by: I. E. Mizikovskii
Published: (2021-07-01)

Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia
by: Juan Gabriel Piñeros, et al.
Published: (2021-11-01)

Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older
by: Kosaku Komiya, et al.
Published: (2025-07-01)

[Complementary Strategy of RSVpreF Vaccination/Nirsevimab versus Nirsevimab Alone for the Prevention of RSV Infection in Infants in Italy: A Cost-Minimization Analysis]
by: Giorgio Lorenzo Colombo, et al.
Published: (2025-07-01)

Economic impact of RSV infections in young children attending primary care: a prospective cohort study in five European countries, 2021 to 2023
by: Jojanneke van Summeren
Published: (2025-05-01)

Catastrophic costs of Tuberculosis in patients registered under the National Tuberculosis Elimination Programme in South-East Delhi, India
by: Tazean Zahoor Malik, et al.
Published: (2025-07-01)

Impact of Respiratory Syncytial Virus (RSV) in Adults 60 Years and Older in Spain
by: Sara Jimeno Ruiz, et al.
Published: (2024-11-01)

Improving the quality of care of respiratory syncytial virus in the neonatal and pediatric populations globally
by: Fungwe Jah, et al.
Published: (2025-05-01)

ACUTE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN CHILDREN IN THE AGE ASPECT
by: V. B. Rovny, et al.
Published: (2015-08-01)

Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region
by: Adel S. Alharbi, et al.
Published: (2024-09-01)

Problems of classification of indirect expenses in road building
Published: (2020-01-01)

Generation of nanobodies against the F protein of respiratory syncytial virus and establishment of an indirect immunofluorescence assay
by: Qianqian Wang, et al.
Published: (2025-07-01)

Cost of TB care and equity in distribution of catastrophic TB care costs across income quintiles in India
by: Kathiresan Jeyashree, et al.
Published: (2024-12-01)

Circulation of Respiratory Syncytial Virus (RSV) in Poland Between Seasons of 2009/2010 and 2022/2023 Based on SENTINEL System
by: Karol Szymański, et al.
Published: (2025-01-01)

Genotypic Characterization of Human Respiratory Syncytial Viruses Detected in Mexico Between 2021 and 2024
by: Nadia Martínez-Marrero, et al.
Published: (2025-04-01)

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
by: Andreea Calomfirescu-Avramescu, et al.
Published: (2025-02-01)

Epidemiology and genetic diversity of human respiratory syncytial virus in Belgium between 2011 and 2019
by: Kaat Ramaekers, et al.
Published: (2024-10-01)

Healthcare Resource Utilization and Economic Outcomes of RSV-Hospitalized Patients Aged ≥ 60 Years: A Retrospective Cohort Study
by: Anna Puggina, et al.
Published: (2025-02-01)

CLINICAL AND PATHOMORPHOLOGICAL MANIFESTATIONS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION. CASE REPORT
by: I. V. Babachenko, et al.
Published: (2018-04-01)

Characteristics of respiratory syncytial virus infection in children in Pudong New Area， Shanghai， 2013‒2023
by: YU Qiumiao, et al.
Published: (2025-05-01)

Prevention of respiratory syncytial virus disease across the lifespan in Italy
by: Paolo Manzoni, et al.
Published: (2025-04-01)